Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
41.37
-2.28 (-5.22%)
At close: Nov 20, 2026, 4:00 PM EST
41.40
+0.03 (0.07%)
After-hours: Nov 20, 2026, 7:30 PM EST
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $105.86. The average 1-year stock price forecast is 155.89% higher than the current stock price, while the lowest is $73 (+76.46%) and the highest is $126 (+204.57%).
Price Target: $105.86 (+155.89%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 9 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $108 → $105 | Buy | Maintains | $108 → $105 | +153.81% | Nov 17, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 13, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $100 | Buy | Reiterates | $100 | +141.72% | Nov 13, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $120 → $106 | Buy | Maintains | $120 → $106 | +156.22% | Nov 13, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Reiterates $109 | Buy | Reiterates | $109 | +163.48% | Nov 13, 2026 |
Financial Forecast
Revenue This Year
312.04M
from 450.82M
Decreased by -30.78%
Revenue Next Year
532.25M
from 312.04M
Increased by 70.57%
EPS This Year
-5.79
from -3.61
EPS Next Year
-4.03
from -5.79
EPS and Forward PE are based on non-GAAP adjusted numbers.